China’s Medical Insurance Spending Tops 3 Trillion Yuan

China’s basic medical insurance fund expenditures exceeded 3 trillion yuan (approximately US$414 billion) for the first time in 2025, according to the annual statistical bulletin released by the National Healthcare Security Administration (NHSA). The milestone underscores both the expanding scale of the world’s largest healthcare safety net and a significant improvement in the system’s financial sustainability.

The NHSA’s “2025 National Medical Insurance Development Statistical Bulletin” revealed that total fund income reached 3.587 trillion yuan (up 2.7% year-on-year) while total expenditures hit 3.001 trillion yuan (up 0.8% year-on-year), as reported by Sina News. Crucially, income growth outpaced expenditure growth for the first time in recent years, reversing a concerning trend that had raised questions about the long-term viability of the system.

Coverage Expands Even as Population Declines

Despite China’s total population declining by 3.39 million in 2025, the number of people covered by basic medical insurance increased by 4.06 million to reach 1.3307 billion, maintaining a coverage rate of 95%. As Southern Metropolis Daily noted, industry experts described this as “the result of people voting with their feet,” reflecting broad public confidence in the system.

The insured population also underwent a structural shift. Urban Employee Basic Medical Insurance (UEBMI) — which commands higher contribution rates and offers richer benefits — added 9.08 million new enrollees, raising its share of total insured to 29.2%. This shift toward higher-contributing members has strengthened the fund’s revenue base.

Where the Money Goes

The 3 trillion yuan in expenditures reflects a system increasingly focused on outpatient care and innovative treatments. Outpatient reimbursements surged 25.51% year-on-year to 7.215 billion visits, while hospitalizations actually declined by 3.40%, signaling a successful policy push toward community-based care, according to Haibao News.

Cross-province medical settlement — a key convenience reform — continued to expand rapidly. The system processed 15.82 million inpatient cross-province direct settlements and 292 million outpatient cross-province visits, dramatically reducing the burden on migrant workers and their families who previously had to return to their home provinces to claim reimbursement.

Innovation Funding Through “Cage Emptying”

A central pillar of China’s healthcare strategy has been the “emptying the cage to change the bird” (腾笼换鸟) approach: savings from generic drug price cuts via centralized procurement are redirected to fund innovative therapies. Between 2018 and 2025, negotiated innovative drugs generated over 7.1 trillion yuan in sales, with the medical insurance fund contributing more than 4.8 trillion yuan.

The National Reimbursement Drug List now contains 3,253 drugs (1,857 Western and 1,396 traditional Chinese medicines), with 114 new drugs added in 2025 alone. The year also saw the first edition of the Commercial Health Insurance Innovative Drug Catalog, which includes 19 high-cost drugs beyond basic insurance scope.

Chen Zhu (陈竹), Chief Analyst for the Healthcare Industry at CITIC Securities, told Sina News that the industry is closely watching three policy levers: the first-launch pricing mechanism for new drugs, adjustments to the Essential Drug List, and commercial insurance promotion policies. “Under the principle of ‘stabilizing clinical use, ensuring quality, preventing collusion, and opposing involution,’ attention is focused on optimizing both ‘volume’ and ‘price’ dimensions in procurement results,” Chen said.

Anti-Fraud Crackdown Intensifies

The NHSA recovered 34.2 billion yuan in fraudulent claims in 2025, with 10,357 suspects arrested and 1,626 fraudulent institutions identified. A nationwide drug traceability code system — collecting over 100 billion codes from more than 1.02 million institutions — has fundamentally reshaped compliance incentives, making it far harder to resell government-subsidized drugs on the black market.

This enforcement momentum has continued into 2026. According to China News Service via JW View, the NHSA recovered an additional 16.35 billion yuan in the first half of 2026 and handled 130,000 violators. The agency has deployed a three-tier defense system of pre-treatment alerts, real-time auditing, and post-treatment review to catch abuse before payments are made.

Demographic Pressures and Policy Responses

China’s rapidly aging population continues to drive healthcare demand. By 2025, nearly 310 million people were covered by long-term care insurance, and the inclusion of assisted reproductive technology in basic insurance — a first — resulted in 3.24 million treatments nationwide, benefiting over 1.6 million people. All provinces now offer direct maternity benefit payments to individuals, with maternity insurance enrollment increasing by 6.66 million.

NHSA Deputy Director Zhang Chenguang (张晨光) said the data demonstrates “stable insurance coverage scale, a larger and more stable medical insurance fund, and equal emphasis on serving high-quality population development and promoting economic and social development.”

What’s Next

The 12th round of national centralized drug procurement closed on July 16, 2026, with over 4,500 medical institutions and 530 pharmaceutical enterprises participating across 65 drug categories. The new round introduces mechanisms to penalize ultra-low bidding, including reducing allocation volumes to zero for bids falling more than two standard deviations below the average入围 price.

Looking ahead, analysts project that commercial health insurance could contribute 300 billion yuan in payments to China’s healthcare industry by 2030, potentially unlocking a new funding stream for innovative therapies beyond the basic insurance system. The “15th Five-Year Plan” for national health has called for deeper integration of commercial insurance with basic coverage, signaling that China’s multi-tiered healthcare financing system is still evolving.

For the 1.33 billion people covered by China’s basic medical insurance, the 3 trillion yuan milestone represents both a measure of the system’s immense scale and a reminder of the challenges ahead as the population ages and demand for cutting-edge treatments grows.